Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Pfizer, Moderna seen reaping billions from COVID-19 vaccine booster market

Stock Markets Aug 13, 2021 12:46PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
4/4 © Reuters. FILE PHOTO: A migrant worker receives a jab while being injected with the one-dose Sputnik Light vaccine against the coronavirus disease (COVID-19) in a vaccination centre at a city market in Moscow, Russia, June 30, 2021. REUTERS/Tatyana Makeyeva/File Ph 2/4

By Michael Erman

NEW YORK (Reuters) -Drugmakers Pfizer Inc (NYSE:PFE), BioNTech and Moderna (NASDAQ:MRNA) Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say.

For several months, the companies have said they expect that fully inoculated people will need an extra dose of their vaccines to maintain protection over time and to fend off new coronavirus variants.

Now a growing list of governments, including Chile, Germany and Israel, have decided to offer booster doses to older citizens or people with weak immune systems in the face of the fast-spreading Delta variant.

Late on Thursday, the U.S. Food and Drug Administration authorized a booster dose of vaccines from Pfizer Inc and Moderna Inc for people with compromised immune systems.

Pfizer, along with its German partner BioNTech, and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.

Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.

    The vaccine makers say that evidence of waning antibody levels in vaccinated people after six months, as well as an increasing rate of breakthrough infections in countries hit by the Delta variant, support the need for booster shots.

Some early data suggests that the Moderna vaccine, which delivers a higher dose at the outset, may be more durable than Pfizer’s shot, but more research is needed to determine whether that is influenced by the age or underlying health of the people vaccinated.

    As a result, it is far from clear how many people will need boosters, and how often. The profit potential of booster shots may be limited by the number of competitors who enter the market. In addition, some scientists question whether there is enough evidence that boosters are needed, particularly for younger, healthy people. The World Health Organization has asked governments to hold off on booster shots until more people worldwide receive their initial doses.

    "We don't know what the market forces will be," Moderna President Stephen Hoge said in an interview last week. "At some point, this will become a more traditional market - we'll look at what are the populations at risk, what value are we creating, and what are the number of products that serve that value. That will ultimately impact price."

Pfizer declined to comment for the story. During the company’s second-quarter earnings call, executives said they believe a third dose will be necessary 6 to 8 months after vaccination, and regularly afterward.

    A MODEL IN FLU SHOTS

    If regular COVID-19 boosters are needed among the general population, the market would most resemble the flu shot business, which distributes more than 600 million doses per year. Four competitors split the U.S. flu market, which is the most lucrative and accounts for around half the global revenue, according to Dave Ross, an executive at CSL (OTC:CSLLY)'s flu vaccine unit Seqirus.

    Flu vaccination rates in developed countries have settled at around 50% of the population, and COVID boosters would likely follow a similar pattern if approved widely, said Atlantic Equities analyst Steve Chesney.

    Flu shots cost around $18 to $25 a dose, according to U.S. government data and competition has kept price increases in check, with producers raising prices 4 or 5 percent in 2021.

    Pfizer and Moderna may have greater pricing power for their boosters, at least at the outset, until competitors arrive. Pfizer initially charged $19.50 per dose for its vaccine in the United States and 19.50 euros for the European Union, but has already raised those prices 24% and 25%, respectively, in subsequent supply deals.

    AstraZeneca Plc and Johnson & Johnson (NYSE:JNJ) are both gathering additional data on boosters of their vaccines. Novavax (NASDAQ:NVAX), Curevac, and Sanofi (NASDAQ:SNY) could also potentially be used as boosters, though their vaccines have yet to receive any regulatory authorization.

    "A lot of these firms aren't even in the market yet. I think within a year's time, all these companies will have booster strategies," said Morningstar analyst Damien Conover, who covers Pfizer.

    Mizuho Securities analyst Vamil Divan expects at least 5 players in the COVID-19 booster market within a few years.

There's still a lot of uncertainty around how boosters would be rolled out in the United States. Still, it is possible or even likely that people will be boosted with different vaccines than they were originally vaccinated with. The National Institute of Allergy and Infectious Diseases is already testing mixed boosting, and other countries that have used so-called mix and match vaccination have not had problems with that strategy.

   One factor that could curb prices is if the U.S. government continues paying for most or all of the shots administered in the country, rather than leave it in the hands of private health insurers. In that scenario, the government would still be negotiating prices directly with vaccine makers, and could use its buying power to stave off price increases.

    Bijan Salehizadeh, managing director at healthcare investment firm Navimed Capital, said the U.S. government is likely going to want to keep paying in order to keep vaccination rates high and prevent new COVID surges, particularly if a Democratic administration is still in power.

"It's going to be paid for until the virus disappears or mutates to be less virulent," Salehizadeh said.

Pfizer, Moderna seen reaping billions from COVID-19 vaccine booster market
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (6)
Ominous Owl
Ominous Owl Aug 13, 2021 2:20PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hoard & protect as many weaklings as possible & they will form mobs & drive powerful democracies to communism because of their incompetence. Declare vaccine opposers as threats to National Security & deal ruthlessly.
Me comment
Me comment Aug 13, 2021 2:03PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why do you think they are pushing so hard for it, an annual revenue stream for them.
Francesco Lucchesi
Francesco Lucchesi Aug 13, 2021 9:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
unbelievable fraud
Francesco Lucchesi
Francesco Lucchesi Aug 13, 2021 9:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
which is why I will never ever ever take it. I'd rather spread my germs around
andy matalobos
andy matalobos Aug 13, 2021 9:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Your stupidity combines with arrogance is the fuel for this delta variant. Crawl back to your cave.
Felipe Daniel
Felipe Daniel Aug 13, 2021 9:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
andy matalobos vaccinated can be infected and infect others
John Snowden
John Snowden Aug 13, 2021 8:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
"The Merger of State and Corporate Powers..."
Yankee Steve
Yankee Steve Aug 13, 2021 7:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The big pharmas see 🤑🤑🤑 and KaChing! Ringing. Nobody including WHO, NIH or medical health officers mentioned about strengthening your immune system with Vitamin C, D3, zinc to strengthen your immune system. What a farce
brett fry
brett fry Aug 13, 2021 7:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The only alternative is that they dont make billions but then millions die. I assume all of your friends and family are in perfect health and can survive just by taking vitamins. Either way, stop spreading misinformation that could kill people.
John Healy
John Healy Aug 13, 2021 7:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Also, using a nutritional supplement called Quercetin may be useful. It acts as a zinc ionophore transporting zinc into the mitochondria thereby disrupting viral replication. For some solid information regarding Covid-19, including ways to bolster the immune system, check out Medcram on YouTube. Dr. Seheult is a frontline pulmonologist and provides objective opionions and data on the prevention and treatment of Covid-19. Although the channel is primarily focused on giving information for medical professionals, there is plenty of useful material for the layperson as well.
Francesco Lucchesi
Francesco Lucchesi Aug 13, 2021 7:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
brett fry they die anyway
brett fry
brett fry Aug 13, 2021 7:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Francesco Lucchesi being careful rarely kills, being ignorant does. Good luck
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email